These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 27673288)

  • 1. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive nephrectomy: A medical oncologist's perspective.
    Dizman N; Maia MC; Pal SK
    Urol Oncol; 2017 May; 35(5):180-182. PubMed ID: 29037531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.
    García-Perdomo HA; Zapata-Copete JA; Castillo-Cobaleda DF
    Investig Clin Urol; 2018 Jan; 59(1):2-9. PubMed ID: 29333508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
    Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
    Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
    Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
    Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
    Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
    Meza L; Chehrazi-Raffle A; Pal SK
    Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in the era of targeted therapies: a review.
    Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
    BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Graham J; Bhindi B; Heng DYC
    Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
    Hsiang WR; Kenney PA; Leapman MS
    Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
    Ghandour RA; Singla N; Margulis V
    Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.
    Karam JA; Babaian KN; Tannir NM; Matin SF; Wood CG
    Minerva Urol Nefrol; 2015 Jun; 67(2):149-56. PubMed ID: 25645343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.